PTC Therapeutics wins auction for Sangamo’s ST-920 Fabry gene therapy in deal worth up to $211 million

The acquisition would add a BLA-stage, one-time AAV gene therapy to PTC’s rare disease portfolio, with a rolling US submission expected to complete in the fourth quarter of 2026.

PTC Therapeutics has been selected as the winning bidder in a competitive bankruptcy auction to acquire ST-920, Sangamo Therapeutics’ BLA-stage AAV gene therapy for Fabry disease, for $111 million upfront plus up to $100 million in regulatory milestones.

The transaction gives PTC a late-stage rare disease programme that could use its existing gene therapy and global commercial infrastructure, with a potential US launch in 2027 if the BLA is completed and subsequently approved.

Field	Content
Alert Type	Deal
Companies	PTC Therapeutics; Sangamo Therapeutics
Deal Type	Asset acquisition following competitive bankruptcy auction
Asset or Company	ST-920 (isaralgagene civaparvovec)
Therapy Area(s)	Rare disease; Fabry disease
Technology or Modality	One-time AAV gene therapy
Deal Value	$111 million upfront, plus up to $100 million in regulatory milestone payments, giving a maximum potential transaction value of $211 million. The additional $100 million is contingent and should not be treated as guaranteed consideration. (Yahoo Finance)
Development Stage	BLA-stage; rolling US Biologics License Application submission underway
Geography	Global
What Happened	On 12 August 2026, PTC Therapeutics announced that it had been selected as the winning bidder to acquire ST-920 from Sangamo Therapeutics through a competitive bankruptcy auction. PTC will pay $111 million upfront and could pay a further $100 million tied to regulatory milestones. ST-920 is a one-time AAV gene therapy designed to deliver a functional copy of the GLA gene in people with Fabry disease. The programme is already at BLA stage, with completion of the rolling US submission expected in the fourth quarter of 2026. The acquisition remains subject to the applicable bankruptcy court approval and closing process. (Yahoo Finance)
Why It Matters	PTC is acquiring a regulatory-stage gene therapy rather than an early clinical programme, limiting the additional development required before a potential US regulatory decision. ST-920 also fits PTC’s existing focus on rare diseases and gene therapy, allowing the company to use established infrastructure rather than building a new commercial organisation specifically for the asset. PTC has identified the programme as an opportunity to support short- and intermediate-term revenue growth, although this remains dependent on regulatory approval and successful commercialisation. (Yahoo Finance)
Supporting Context	Fabry disease is an X-linked lysosomal disorder caused by variants in the GLA gene, resulting in deficient alpha-galactosidase A activity and progressive accumulation of disease-associated substrates. ST-920 has been evaluated in the Phase I/II STAAR study and is designed to enable sustained production of alpha-galactosidase A following a single administration. (Sangamo)
Strategic Rationale	PTC gains a BLA-stage rare disease asset that complements its existing global commercial and gene therapy capabilities without requiring the lengthy development timeline associated with acquiring an earlier-stage programme. Sangamo’s bankruptcy process, meanwhile, provides a mechanism to monetise the ST-920 programme through the asset sale.
Potential Impact	If the BLA is successfully completed and FDA approval follows, ST-920 could give PTC a commercial-stage Fabry disease gene therapy as early as 2027. Its eventual clinical and commercial contribution will depend on regulatory review, the durability and safety of the therapy and adoption within the existing Fabry treatment landscape.
Key Takeaway	The acquisition gives PTC a BLA-stage Fabry gene therapy with near-term regulatory potential for $111 million upfront, substantially accelerating its opportunity to add another commercial rare disease product.
What to Watch	Bankruptcy court approval and transaction closing, completion of the rolling BLA in the fourth quarter of 2026, subsequent FDA review and whether ST-920 remains on track for a potential 2027 US launch. (Yahoo Finance)
Primary Source	PTC Therapeutics acquisition announcement
Relevant Date	12 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com